ESR2 and ovarian carcinoma: In addition, this effect of ERβ in GCT would be different from that described in other cancers, wherein this receptor is generally described as an anti-proliferative factor that is down-regulated in breast (BC), prostate (PC), and epithelial ovarian cancers (OC) [67,69,149].